The aim of this study is to assess if common genetic variants located in the CDKN1B locus, coding for the cell cycle inhibitor p27
Introduction
Cancers that arise in the thyroid gland account for 1% of all neoplasias. More than 95% of thyroid carcinomas are derived from follicular cells or thyrocytes, the thyroid hormone-producing cell lineage in the gland (DeLellis 2004) . Among the neoplasias arising from thyroid follicular cells, 'papillary thyroid carcinoma' (PTC) and 'follicular thyroid carcinoma' (FTC) represent the two most common subtypes (85 and 10% respectively; Kondo et al. 2006) . A minority of the thyroid tumours (3%), referred to as 'medullary thyroid carcinoma' (MTC), arise from a different cell lineage, the parafollicular or C-cells, which are involved in calcitonin secretion (Randolph & Maniar 2000) .
Different genetic alterations, all of them involving the RET/MAP kinase pathway, have been described as subtype-specific somatic causal changes in PTC and FTC (Santoro et al. 1990 , Greco et al. 1992 , Davies et al. 2002 , Nikiforov 2002 , Kondo et al. 2006 . Although some genes related to thyroid cancer development as part of familial syndromes are known (Mulligan et al. 1993 , Hofstra et al. 1994 , there are few data on genetic risk factors related to the susceptibility for developing sporadic thyroid carcinomas (Cebrian et al. 2005 , Ruiz-Llorente et al. 2007 . The identification of low-penetrance genes (LPGs) related to follicular cell-derived carcinoma is an arduous task due to the heterogeneity and relative rarity of the disease. A well-known approach, which compensates this problem and increases the probability of finding genetic risk factors related to the disease, is the selection of single nucleotide polymorphisms (SNPs) within candidate genes or loci for the development of thyroid cancer.
The CDKN1B gene encodes p27 Kip1 , an inhibitor of the cyclin/cyclin-dependent kinase (Cdk) complexes (Sa et al. 2005) , which are essential for cell cycle progression. Loss of expression of p27 Kip1 protein has been described as a frequent event in several human cancers (Slingerland & Pagano 2000 , Chu et al. 2008 , apparently conferring a proliferative advantage that can lead to tumour formation. This behaviour first suggested a tumour suppressor role of p27 Kip1 , but it does not fit all classic features, since it is rarely mutated in cancer (Kawamata et al. 1995 , Kossatz & Malek 2007 , Lindberg et al. 2007 . Alternative mechanisms acting at the post-transcriptional level have been suggested, including a lower translation rate of CDKN1B mRNA (Hengst & Reed 1996) ; an increase in protein degradation, specifically by the Scf-Skp2 E3 ubiquitin-protein ligase (Pagano et al. 1995 , Chiappetta et al. 2007 ; and the cytosolic mislocalization of p27 Kip1 protein (Viglietto et al. 2002 , Min et al. 2004 . CDKN1B plays a key role in the aetiology of thyroid cancer. Several lines of evidence from clinical and in vitro studies demonstrate that somatic loss, underexpression (Khoo et al. 2002) or mislocalization (Baldassarre et al. 1999) 
of p27
Kip1 may contribute to the process of thyroid carcinogenesis. In addition, it has been demonstrated that the phosphatidylinositol-3-kinase (PI3K)/AKT pathway controls thyroid cell proliferation by regulating the expression and subcellular localization of p27 (Baldassarre et al. 1999 , Khoo et al. 2002 , Motti et al. 2005 , and therefore, CDKN1B (p27 Kip1 ) represents a good candidate gene for a classical case-control study. In view of these antecedents, the aim of the present study was to assess whether common, potentially functional, genetic variants within the CDKN1B gene could influence the risk for thyroid cancer. Thus, based on a scan of the literature and the use of bioinformatics tools, three potentially functional SNPs in the CDKN1B gene were selected: K838COA (rs36228499), K79COT (rs34330) and 326TOG (V109G, rs2066827) .
Here, we propose that the K79COT (rs34330) polymorphism acts as a genetic risk factor for thyroid cancer by affecting the transcription rate, as indicated by the functional assays performed in this study.
Subjects and methods
Patients A total of 649 Spanish patients with sporadic thyroid cancer were recruited for a multicentre hospital-based study. The main thyroid cancer subtypes were represented in this series: 274 MTC, 328 PTC, composed of 193 'classic PTC' (cPTC) and 129 'follicular variant PTC' (FVPTC), and 47 FTC. Diagnoses were assessed by pathologists from the different institutions that participated in the study.
Controls
We selected a series of 385 healthy, representative Spanish controls, all of them cancer free and without any thyroid pathology, according to their responses to a general clinical questionnaire.
Mean age and gender distribution were similar in controls and cases (Mann-Whitney's U and KruskalWallis associated P values O0.05).
Informed consent was obtained from all subjects included in the study.
DNA and RNA isolation
Genomic DNA was extracted from the blood of 591 patients following a standard method (Sambrook et al. 1989) . The remaining 58 DNA samples were obtained from patients' saliva using the Oragene DNA SelfCollection Kit (DNA Genotek, Ottawa, Ontario, Canada). Control DNAs were isolated from peripheral blood lymphocytes using automatic DNA extraction according to the manufacturer's instructions (Magnapure, Roche).
Total RNA was isolated from lymphocytes of 97 controls following the standard TRIzol Reagent method (Invitrogen).
SNP selection
Fifteen CDKN1B polymorphisms are described in the International HapMap Project database (http://www. hapmap.org/, release 21a/phaseII), considering the I Landa, C Montero-Conde et al.: CDKN1B SNP is a risk factor for thyroid cancer www.endocrinology-journals.org region that spans from 5 kb upstream to 1 kb downstream of the gene. We applied two filters in the SNP selection: the allele frequency (at least a minor allele frequency (MAF) of 0.05 in the HapMap-CEU population) and a predicted functionality. Seven of the fifteen variants passed the first filter, and only three of these (K838COA (rs36228499), K79COT (rs34330) and 326TOG (V109G, rs2066827)) showed consistent functional predictions (at least two different algorithms predicted the same result) according to the PupaSuite (Conde et al. 2006 ) and F-SNP (Lee & Shatkay 2008 ) bioinformatics tools. Nucleotide positions are numbered relative to the start of translation according to the Genbank accession number AB003688. Predicted functionality was reinforced by previously published data as described below. The K838COA lies within the promoter region of p27
Kip1
, and it has been associated with an increased risk of myocardial infarction (Gonzalez et al. 2004 ). The K79COT is a polymorphism within the 5 0 untranslated region (5 0 UTR) of p27 Kip1 , which has been shown to contain promoter activity (Minami et al. 1997 , Ito et al. 1999 , Liu et al. 2005 , and has been previously associated with cancer (Chang et al. 2004 , Wang et al. 2007a , Driver et al. 2008 . Finally, 326TOG (V109G) is a non-synonymous variant in exon 1, which has been also associated with susceptibility to cancer (Kibel et al. 2003 , Gayther et al. 2007 .
According to the HapMap, there is some linkage disequilibrium along the CDKN1B region between rs36228499 and rs34330, but they do not show a high correlation. Thus, the three mentioned SNPs were assessed as independent putative genetic risk factors.
Genotyping platforms
Two different genotyping strategies were used to evaluate the three polymorphisms: a TaqMan genotyping assay (Applied Biosystems, CA, USA) for SNPs rs34330 and rs2066827, and a restriction fragment length polymorphism (RFLP) approach for rs36228499.
Taqman platform
Probe accuracy to discriminate the two alleles at a specific locus was initially checked in a set of 24 DNA samples. Genotyping specificity was assessed by including two DNA duplicates and a negative control in each 96-well plate genotyped, yielding 100% consistent replication results. In addition, we genotyped cases and controls in the same run. The reaction was performed at the default conditions recommended by the manufacturer: an initial denaturing step of 10 min at 95 8C, followed by 40 cycles of 15 s of denaturation at 92 8C, and 1 min of annealing and extension at 60 8C. Samples without a genotype call under these conditions were excluded for further analyses.
RFLP technique rs36228499 was genotyped as described by Gonzalez et al. (2004) . To improve the amplification intensity and, thus, the assay resolution, we designed a nested PCR, using the following primer sequences and PCR conditions: first PCR: K838_F: 5 0 -GACCTTCGCG-GTCCTCTG-3 0 ; K838_R: 5 0 -GTGACTGCTGGAG-GGGTACT-3 0 ; temperature of annealing, TaZ58 8C, 40 cycles; second PCR: K838N_F: 5 0 -TCCAGGTCCCGGCTTCCCGGt-3 0 ; K838N_R: 5 0 -CCTGCTCT-GGCTGGCCTCGGAG-3 0 ; TaZ65 8C, 35 cycles. The K838N_F primer included a mismatch (shown in lower case) to create a TaqI restriction endonuclease site when K838C was present. Amplicons were subsequently digested by TaqI (Fermentas, Burlington, Ontario, Canada), and the products were separated in a 3.5% agarose D1 medium (Pronadisa, Torrejón de Ardoz Spain) gel electrophoresis run (data not shown). Enzymatic digestion yielded fragments of 173 bp (undigested, corresponding to the polymorphic AA genotype), 152C21 bp (digested, wild-type CC genotype) or both (CA heterozygotes).
DNA sequencing
Accuracy of both TaqMan and RFLP genotyping was confirmed by direct sequencing of randomly selected samples that represented 5% of the total samples. Regions containing the studied SNPs were amplified by PCR prior to sequencing using the following additional primers and conditions: K79_F:
0 ; TaZ58 8C, for K79C OT; and 109_F: 5 0 -AAGAGTTAACCCGGGAC-TT-3 0 ; 109_R: 5 0 -CTCTCCCAAAGCTAAATCAG-3 0 , TaZ56 8C, to interrogate the V109G variant. DNA sequencing was carried out using an ABI 3730xl sequencer (Applied Biosystems).
Construction of p27
Kip1 reporter vector
The K79COT SNP lies within the promoter/5 0 UTR of the CDKN1B gene. Therefore, we cloned the minimal regulatory region of the CDKN1B gene that has been shown to be able to efficiently drive transcription of a downstream reporter gene (Minami et al. 1997 , Ito et al. 1999 , Liu et al. 2005 . DNA fragments from the 5 0 region of the CDKN1B gene between nucleotides K575 and K1 (AB003688), containing either C or T at position K79, were generated through PCR using genomic DNA of homozygous CC and TT individuals with forward (GGTACCGGTACCCCACCTTAAGGCCGCGCT-CG) and reverse (AAGCTTAAGCTTCTTTCTCCC-GGGTCTGCACG) primers containing KpnI and HindIII sites respectively. PCR products were cloned into the pGL3-Basic promoterless plasmid (Promega) to generate pGL3-p27 Kip1 C (K79C) and pGL3-p27
Kip1 T (K79T) in order to drive the expression of the downstream luciferase gene. Plasmids generated for each genotype were confirmed by direct sequencing.
Cell culture and transfections
HeLa cells (American Type Culture Collection, Manassas, VA, USA) were incubated at 37 8C in a humidified 5% CO 2 -95% O 2 atmosphere in DMEMhigh glucose medium (Sigma-Aldrich) supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin and 10% foetal bovine serum. The rat thyroid cell line PCCl3 was cultured in F-12 Coon's medium (Euroclone, Pero-Milano, Italy) supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin, 5% newborn calf serum, 20 ng/ml glycyl-histidyl-lysine (GHL; Sigma), 3.6 ng/ml hydrocortisone (Sigma), 10 mg/ml insulin from bovine pancreas (Sigma), 5 mg/ml human apo-transferrin (Sigma), 10 ng/ml somatostatin (Sigma) and 0.5 mU/ml TSH (Sigma). Transfections were performed with Trans lT-LT1 Transfection Reagent (Mirus, Madison, WI, USA) following the manufacturer's protocol.
Luciferase reporter gene assays
For luciferase activity assays, cells were transfected with 1 mg of the promoter/luciferase reporter gene (pGL3-p27 Kip1 C or pGL3-p27 Kip1 T ), with 100 ng of pRL Renilla as the control vector (Promega) to correct for differences in transfection efficiency. Cells were collected 24 and 48 h after transfection by centrifugation, washed twice with PBS and lysed with 100 ml of cell lysis reagent (Dual-Luciferase Reporter Assay System, Promega). Cell lysates were dispensed into luminometer plates, followed by sequential autoinjection of the Luciferase Assay Reagent for firefly luciferase activity measurement, and Stop & Glo Reagent for Renilla luciferase activity measurement (Dual-Luciferase Reporter Assay System, Promega). Basal luciferase activity was checked in cells transfected with an empty vector (pGL3 Basic Vector). Three independent transfections were performed for each construct (pGL3 Basic Vector, pGL3-p27 Kip1 C or pGL3-p27 Kip1 T ) in triplicate.
cDNA synthesis and real-time quantitative reverse transcription-PCR
We obtained cDNA from RNA that was isolated from lymphocytes of 97 healthy volunteers. We used it to evaluate the genotype-phenotype correlation by means of real-time quantitative PCR (qPCR) to compare the CDKN1B mRNA levels as a function of rs34330 polymorphism genotype. One microgram of total RNA was reverse transcribed using Superscript II Reverse Transcriptase (Invitrogen) and an oligo dT18 primer following the manufacturer's instructions. The amount of CDKN1B mRNA was quantified by real-time PCR with the Sequence Detection System 7900HT (Applied Biosystems) using the specific primers (p27QF: 5 0 -CCCTAGAGGGCAAGTACGAGT-3 0 and p27QR: 5 0 -AGTAGAACTCGGGCAAGCTG-3 0 ), a labelled probe (Universal ProbeLibrary #39, Roche), and the Universal Master Mix (PE Applied Biosystems). The amplification conditions consisted of an initial step at 95 8C for 10 min, followed by 40 cycles of 15 s at 95 8C and 1 min at 60 8C. Standard curves were generated with serial 1:4 dilutions of a sample showing high CDKN1B expression of mRNA. Normalization was carried out with the internal standard b-glucuronidase (GUS) using as a forward primer 5 0 -GAAAATATGTGGTTGGA-GAGCTCATT-3 0 ; as a reverse primer 5 0 -CCGAGT-GAAGATCCCCTTTTTA-3 0 ; and as a probe 5 0 -FAM-CCAGCACTCTCGTCGGTGACTGTTCA-3BQ1-3 0 . All reactions were in the initial part of the exponential amplification phase, and the cycle at which each sample crossed the threshold (C t ) was recorded for CDKN1B and GUS. The DDC t method was used for the calculation of the different amounts of mRNA (Livak & Schmittgen 2001) . Negative controls were included in all PCRs, and assays were carried out in triplicate.
Protein isolation and immunoblot
Nine healthy volunteers carrying rs34330 genotypes equally (CC, CT and TT, three each) were randomly selected to check whether this promoter variant could have an effect at the p27 Kip1 protein level. Whole protein extraction from blood lymphocytes was performed using RIPA (Invitrogen) buffer according to the manufacturer's recommendations.
Proteins were separated by 12% SDS-PAGE using the XCell SureLock Mini-Cell electrophoresis system (Invitrogen), and were transferred to polyvinylidene fluoride membranes (Immobilon-P Membrane, Millipore, Billerica, MA, USA). Equal loading of proteins was verified by Ponceau S staining. The membranes were blocked, and were then incubated with a 1:500 dilution of the sc-776 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) following the manufacturer's instructions. This is a commercial polyclonal antibody raised against amino acids 1-197 representing full-length p27 Kip1 . After washing, the membranes were incubated with a 1:10 000 dilution of Alexa Fluor 680 anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) secondary antibody, and the corresponding fluorescence signal was visualized using a LI-COR Odyssey Blot scanner. Equal protein loading was assessed by using a 1:1000 dilution of anti-a-tubulin (DM1A; Abcam, Cambridge, UK).
Protein quantification was done using Odyssey 2.1 software. Both p27
Kip1 and a-tubulin (aTUB) band intensities were corrected by subtracting the intensities of their respective backgrounds. Final p27 Kip1 expression was represented as relative units, resulting from p27
Kip1 /aTUB protein intensity ratios.
Statistical analysis
Departure from Hardy-Weinberg equilibrium (HWE) for all SNPs was tested in the controls using Fisher's exact test (command available online at http://ihg2. helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl). Associations between each SNP and thyroid cancer risk were assessed using Pearson's c 2 test. Genotype frequencies in cases and controls were compared, and odds ratios (ORs) were estimated directly from contingency tables using homozygotes of the more frequent allele in controls as the reference group. For each SNP, the best fitting model was determined by parsimony based on the corresponding associated P values.
When the unadjusted P value was found to be significant, further analyses were performed to adjust for putative confounding factors such as age and gender. Age was recodified as a new variable using the mean as the cut-off value. Mantel-Haenszel test was performed stratifying by gender and age. OR homogeneity was also tested by executing Tarone's test. Finally, stepwise conditional logistic regression method was used to discard age and gender as confounders.
For analyses of luciferase assays, comparisons between means were performed using Student's t-test. We used Mann-Whitney's U test to compare medians from qPCR assays by genotype.
Statistical tests were performed using SPSS for Windows 11.0 and GraphStat programs.
Results
Polymorphism rs34330 (K79COT) is significantly associated with the FVPTC The K838COA (rs36228499), K79COT (rs34330) and 326TOG (V109G, rs2066827) SNPs among the available Spanish cases and controls were genotyped to determine whether a significant association existed between them and thyroid cancer. Controls fulfilled HWE for all three SNPs (Table 1) .
While V109G and K838COA variants did not show significant associations with any of the thyroid cancer subtypes analyzed, rs34330 (K79COT) was identified as a risk factor for developing the FVPTC. According to these results, the polymorphic TT genotype of rs34330 was significantly overrepresented in FVPTC patients. The variant fit a recessive model (ORZ2.12; 95% confidence interval (CI)Z1.09-4.15; P valueZ0.023; Tables 2 and 3 ).
The previous association remained statistically significant after correcting for gender and age. We first proved that OR remained homogeneous (P value O0.05) by Tarone's test. Then, we demonstrated that neither gender nor age was acting as a confounding factor in our results by both Mantel-Haenszel test and stepwise conditional logistic regression, which yielded an adjusted ORZ2.01 and P valueZ0.041. Hardy-Weinberg equilibrium P value in controls. c In our control series (no data available in public databases).
Endocrine-Related Cancer (2010) 17 317-328 www.endocrinology-journals.org Polymorphism K79COT decreases CDKN1B transcription rate in luciferase assays Since the CDKN1B K79TT genotype was associated with a statistically significant increased risk in FVPTC patients, we sought to determine whether the K79COT genetic variation had functional consequences for p27
Kip1 expression. In a first set of experiments, we determined the transcriptional capacity of the two CDKN1B variant promoters by transfecting the pGL3 Basic Vector, pGL3-p27 Kip1 C and pGL3-p27 Kip1 T plasmids into HeLa cells. After 48 h in the presence or absence of serum, cells were collected and the transcriptional activity of the two promoter variants was determined by luciferase assay (Fig. 1A) . We observed that the transcriptional activity shown by the variant promoter (p27 Kip1 T ) was significantly lower than that shown by the wild-type promoter (p27 Kip1 C ), both in the presence (P valueZ0.001) and absence (P valueZ0.002) of serum.
Then, we determined the activity of the different variants of the p27 promoter. To this end, HeLa cells were transfected with pGL3-p27 Kip1 C and pGL3-p27 Kip1 T constructs and starved. Starved cells were induced to re-enter the cell cycle by serum administration, and were analyzed for luciferase activity after 0, 12 and 24 h. After normalizing luciferase activity for the internal Renilla control, the average transcriptional activity of pGL3-p27 Kip1 T was consistently lower (by about 50%) than that of pGL3-p27 Kip1 C (Fig. 1B) . The activity of the wildtype CDKN1B promoter (pGL3-p27 Kip1 C ) increased in mid-G1 (12 h after serum administration) and decreased at the G1/S transition (24 h after serum administration), whereas the mutant p27 promoter (pGL3-p27 Kip1 T ) showed similar kinetics but significantly reduced transcriptional activity (P value 0 h Z0.002, P value 12 h !0.001 and P value 24 h !0.001 respectively).
Subsequently, we analyzed the activity of the p27 promoter in thyrocytes. To this end, we used PCCl3 cells, an established, differentiated rat cell line, as a model of thyroid cells. PCCl3 cells were transfected with pGL3-p27 Kip1 C and pGL3-p27 Kip1 T , placed in a medium with or without TSH for 24 and 48 h, and The P values are derived from the recessive model. The P values are derived from the recessive model.
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www.endocrinology-journals.org analyzed for luciferase activity. After normalizing luciferase activity for the internal Renilla control, the average transcriptional activity of pGL3-p27 Kip1 T in thyrocytes was w50% compared with that of pGL3-p27 Kip1 C (P values !0.001; Fig. 2) . Interestingly, the difference in the transcriptional activity of the two promoter variants was more evident when the cells were deprived of TSH.
The K79TT risk genotype exhibits diminished CDKN1B mRNA levels and a tendency towards lower protein levels in lymphocytes from control individuals
To confirm the in vitro data from the transfection experiments, we evaluated CDKN1B mRNA expression by real-time quantitative reverse transcription-PCR in lymphocytes from a series of 97 healthy controls with known K79COT variant genotype.
Genotypic frequencies in this subset were CCZ0.59, CTZ0.36 and TTZ0.05, which were similar to the frequencies exhibited by the HapMap-CEU population. The mean C t values obtained for CDKN1B and GUS were 29.4 and 27.7 respectively. We observed a marginal statistically significant difference between the average CDKN1B mRNA expression of the CC and TT genotypes (P valueZ0.069, Fig. 3A) . This tendency was also observed when we clustered the non-risk CC and CT genotypes, and compared them against the TT risk group (P valueZ0.102, Fig. 3B ). These findings further suggest that the K79TT genotype is associated with decreased CDKN1B mRNA expression.
In addition, immunoblot experiments were performed to further check this downregulation, which suggest a modest effect of K79COT-dependent p27 Kip1 regulation at the protein level in lymphocytes (Fig. 4) . T constructs, and were subsequently starved in serum-free medium for 24 h. Cells were induced to re-enter the cell cycle by the addition of fresh medium supplemented with 10% FCS for 0, 12 and 24 h. At these time points, the cells were harvested, lysed and analyzed for luciferase activity. 
Discussion
This is the first association study to investigate the effects of common genetic polymorphisms of the cell cycle regulator gene CDKN1B (p27 Kip1 ) in thyroid cancer. Regression analysis allowed us to determine that the SNP rs34330 (K79COT), located in CDKN1B promoter, was significantly associated with the FVPTC under a recessive model (ORZ2.12; P valueZ0.023). Furthermore, the functional assays designed to analyze its effect indicated that this SNP plays a role in CDKN1B transcription. This finding is of special relevance because although p27
Kip1 has been widely studied in tumours (Slingerland & Pagano 2000 , Chu et al. 2008 and specifically in thyroid cancer (Erickson et al. 1998 , Tallini et al. 1999 , Vitagliano et al. 2004 , attention has been focused so far on p27
Kip1 translation, degradation and mislocalization. Here, we report for the first time a differential transcription rate of CDKN1B depending on a genetic variant located in its promoter.
The polymorphism rs34330 has been previously associated with some other neoplasias. Chang et al. (2004) described an association of this SNP with hereditary prostate cancer. They reported that the C allele of the variant was over-transmitted from parents to their affected offspring. They also suggested that the polymorphism was able to disrupt a CpG site, a supposition that has not been demonstrated so far.
Moreover, a two-step large-scale association study, involving more than 2200 patients and more than 2200 controls, found the same variant to be associated with an increased risk of breast cancer in the British population (Driver et al. 2008) . They described the same risk genotype (TT) reported here, also fitting a recessive model (ORZ1.22; P valueZ0.013).
In another recent study, this variant was related to the risk of lung cancer (ORZ1.27; 95% CIZ1.01-1.60; Wang et al. 2007a) , and it was especially strong among heavy smokers (ORZ6.24; 95% CIZ1.67-23.34). Kip1 protein expression depending on K79COT genotype. A trend towards lower p27
Kip1 protein levels in K79TT carriers against non-risk genotypes (CCCCT) was observed. p27
Kip1 protein levels are given in relative units (RU), and they resulted from the correction of p27
Kip1 expression with a-tubulin levels in each case (p27 Kip1 /aTUB ratio).
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The authors proposed that due to the location of this SNP, its functional effect might be associated with a reduced p27 Kip1 protein production. Indeed, they remarked that the SNP was located in the 5 0 UTR, where Millard et al. (2000) had described a 'U-rich element' that may bind several factors (HuR, hnRNP C1 and C2) involved in mRNA stability, processing and translation. However, the polymorphism rs34330 lies 27 nucleotides upstream of the consensus U-rich element defined by Millard et al. This fact, along with some contradictory in silico predictions that we obtained for the above-mentioned binding factors (data not shown), leads us to believe that this is not the mechanism underlying the observed SNP effect.
We hypothesized that rs34330 could alter CDKN1B transcription. In fact, two independent tools (CON-SITE and TFSEARCH), based on different algorithms and integrated into the F-SNP database (Lee & Shatkay 2008) , predicted that rs34330 is located within an important transcription factor binding site. Moreover, both tools predicted a differential affinity, and thus binding, of the human transcription factors AP-2a and SP1 to the variant sequences. Especially, for the first factor, binding is predicted to be strongly influenced by the presence of the polymorphism.
The foregoing predictions were backed by a regulation mechanism described for some genes, which contain overlapping AP-2 and SP1 DNAbinding sites (Hilger-Eversheim et al. 2000) . In these cases, gene transcription is regulated by the SP1/AP-2 ratio. This is of special interest, keeping in mind that AP-2a is known to bind CDKN1A p21/cip1 (Zeng et al. 1997) , a gene encoding a cell cycle inhibitor that belongs to the same family as CDKN1B p27/Kip1 . Overall, it is tempting to speculate that the above factors contribute to the functional effect of the polymorphism at least in the FVPTC, but specific functional studies focused on these factors will be necessary to prove this hypothesis.
The functional assays performed in the present study provide sufficient evidence to conclude that rs34330 (K79COT) significantly influences CDKN1B transcription rates.
Thus, it should be considered as an alternative mechanism of p27 Kip1 downregulation in thyroid cancer, independently of the precise transcription factors involved.
Regarding the two polymorphisms that were not found to be associated with thyroid cancer in the present study, there are no studies directly assessing the influence of rs36228499 (K838COA) in cancer. Only a study by Spurdle et al. (2009) provides indirect evidence that this SNP, tagged by the neighbouring polymorphism rs3759216, does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. In contrast with the K838 variant, there are numerous studies that found a significant association between the CDKN1B-coding SNP rs2066827 (V109G) and cancer. Among them, those related to advanced prostate cancer (Kibel et al. 2003) , oral squamous cell carcinoma , invasive epithelial ovarian cancer (Gayther et al. 2007) , high-grade breast tumours (Tigli et al. 2005) and lymph node metastasis in breast cancer (Naidu et al. 2007 ) are worth mentioning. However, our data, based on a large Spanish population, suggest that this amino acid change in p27
Kip1 is not associated with any of the subtypes of thyroid cancer.
Taken together, we suggest that CDKN1B acts as a LPG in thyroid cancer, specifically associated with FVPTC. We propose that the K79COT transition (rs34330) is the causal variant of a differential transcriptional expression of CDKN1B. These conclusions are supported by the following observations: a significant association in this first case-control study performed in thyroid cancer (risk genotype TT overrepresented in FVPTC; ORZ2.12, P valueZ0.023); the absence of a high correlation with neighbouring SNPs around this polymorphism, and the nonsignificant results for rs2066827 and rs36228499, which minimize the possibility of alternative variants being the causal ones; and the functional assays carried out show a tendency towards lower expression of CDKN1B in the presence of the risk genotype (TT) of rs34330, at both mRNA and protein levels. These findings point to an alternative downregulation mechanism of p27 Kip1 , which should be further explored in the cancer field.
Although these results have to be replicated in independent, representative and well-characterized thyroid cancer series, we propose the SNP rs34330, located in the CDKN1B promoter, as a genetic risk factor related to susceptibility for developing FVPTC. A biological explanation could be that the genetic alterations characterizing FVPTC are similar to those described in FTC, and are therefore related to the PI3K/Akt pathway. Regarding this, there are several genetic evidences suggesting that dysregulated PI3K/Akt pathway plays a significant role in the pathogenesis of thyroid tumours, particularly FTC (Hou et al. 2007 , Riesco-Eizaguirre & Santisteban 2007 , Wang et al. 2007b , Liu et al. 2008 . Since p27 Kip1 belongs to this pathway, an alteration in CDKN1B transcription rate caused by rs34330 could be of fundamental importance in these tumours.
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